May 16, 2022 7:43am

Enjoyed Friday’s bounce, be ready to scale out Monday/Tuesday after two (2) up sessions in a row of three (3) positive closes last week

“Let ‘em run, then bolt …

Earnings: Brainstorm Cell Therapeutics (BCLI) and Biostage (BSTG)

Pre-open indications: 9 Sell into Strength and 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.12% ( -38 points), S&P futures are DOWN -0.30% ( -12 points) and NASDAQ futures are DOWN -0.41% ( -51 points) early in the pre-open – so far,


Stock futures fell mixed and fluctuating on Monday,

European stocks were fluctuating trying to recover from last week’s volatility.

Asia-Pacific closed mixed, after China reported disappointing economic numbers as a result of Covid restrictions, South Korea also fell while Australia climbed.



In closing last week on Friday, the Dow rose 466.36 points, or +1.47%, while the S&P 500 climbed +93.81 points or +2.39% and the Nasdaq jumped 434.04 or +3.82% posting its strongest one-day gain since November 2020.

Sector Coverage action: Dropped Pluristem (PSTI) – I do NOT like their inability to report earnings on a Q basis as well as EOY earnings. Adding: Verve Therapeutics (VERV), a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. The company was formerly known as Endcadia, Inc.

Economic Data Docket: Retail earnings season kicks off this week which could give them insight into how retailers are managing inflation, which remains near 40-year highs.


RegMed Investors’ (RMi) closing bell: “session two (2) in a row of three (3) positive closes in the week. How many times are you right about the sector’s moves and relationship to market forces; RMI is more frequently on target with objective, fact and a numbers-based narrative – check the numbers!

Ebb and flow –

Q2/22 –

May - 5 positive and 4 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

RegMed Investors (RMi) - Q1/22 Cell and Gene Therapy Earnings Scorecard Results …


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

SELL into Strength: I anticipate PAIN this week as I state often in this post “I believe, we are renting the upside from last week.”

Alnylam Pharmaceuticals (ALNY) closed up +$5.14 after Thursday’s +$0.91, Wednesday’s -$7.76, Tuesday’s +$5.66 and Monday’s -$12.23 with a negative -$0.11 or -0.09% pre-open indication,

AxoGen (AXGN) closed up +$0.54 to $9.40 with a negative -$0.15 or -1.60%

Beam Therapeutics (BEAM) closed up +$4.01 to $35.45 after Thursday’s +$1.48, Wednesday’s -$5.82, Tuesday’s +$2.49 and last Monday’s -$2.39 with a positive +$0.65 or -1.83% pre-open indication,

CRISPR Therapeutics (CRSP) closed up +$5.69 to $52.23 after Thursday’s +$2.87, Wednesday’s -$3.64, Tuesday’s +$4.08 and Monday’s -$4.78 with a negative -$2.03 or -3.89% pre-open indication,

Editas Medicine (EDIT) closed up +$1.06 to $11.87 after Thursday’s +$0.78 with a negative -$0.01 or -0.08% pre-open indication,

Fate Therapeutics (FATE) closed up +$2.41 to $24.22 <hit a 52-week low at $20.96 on Thursday> with a negative -$0.12 or -0.50% pre-open indication,

Sage Therapeutics (SAGE) closed up +$1.19 to $30.71 after Thursday’s +$0.18 to $29.52, Wednesday’s -$0.76 to $29.34 and Tuesday’s +$2.58 with a positive +$0.54 or +1.76% pre-open indication.

Voyager Therapeutics (VYGR) closed up +$0.32 to $6.45 with a positive +$0.32 or +4.96% pre-open indication.

Intellia Therapeutics (NTLA) closed up +$6.00 after Thursday’s +$2.66, Wednesday’s -$4.46, Tuesday’s +$2.95 and last Monday’s -$6.12 with a positive +$0.55 or +0.55 to $1.13% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed flat again (it was down -$0.89) with 1,811 shares traded after Thursday’s and Wednesday’s 0 shares traded after Tuesday’s flat with 1,845 shares traded and last Monday’s -$0.39 with 6,422 shares traded.

  • WARNING:  Another PPM -private placement – this one for $5.1 M without a price per share notification. Also, the terminal death lawsuit just got settled (4/28) for $6 M with a PPM – a preferred convertible debt financing.  is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?


The BOTTOM LINE: let me repeat from Friday night’s post, “The issue will be pricing sustainability next week as I believe we are only “renting” the upside?” …

Beaten-down stocks led the cell and gene therapy sector for a second (2nd) straight session; but these equities are subject of targeted by sellers and algorithms.

As I continue to maintain, “… investors are NOT in control of daily market driven sector appreciation or downward dives.”

Earnings’ season is STILL upon us with: Brainstorm Cell Therapeutics (BCLI) and Biostage (BSTG) on 5/16 so far.

Q1/22 earnings season is more than three/quarters (3/4) completed (28 of 35 reported) having reported LPS (loss-per-share) results so far MISSING estimates and revenues.

I try to keep it simple … and short!


Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.